Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05039450 · ClinicalTrials.gov registry record · Phase 2
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
A Phase 2 study of NASH - Nonalcoholic Steatohepatitis, sponsored by Akero Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 20
- Study locations
NCT05039450 is a Phase 2 study of NASH - Nonalcoholic Steatohepatitis that is active but no longer recruiting, run by Akero Therapeutics. The registered enrollment target is 182 participants, below the 262-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT05039450, a Phase 2 study of NASH - Nonalcoholic Steatohepatitis, is active but no longer recruiting, sponsored by Akero Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EFX
Study Locations (20)
Florida
- Akero Clinical Study Site - Clearwater
- Akero Clinical Study Site - Fort Myers
- Akero Clinical Study Site - Fort Myers
- Akero Clinical Study Site - Hialeah Gardens
- Akero Clinical Study Site - Lakewood Rch
- Akero Clinical Study Site - Miami Lakes
- Akero Clinical Study Site - Ocala
- Akero Clinical Study Site - Sarasota
Arizona
- Akero Clinical Study Site - Chandler
- Akero Clinical Study Site - Glendale
- Akero Clinical Study Site - Tucson
- Akero Clinical Study Site - Tucson
California
- Akero Clinical Study Site - Fresno
- Akero Clinical Study Site - Long Beach
- Akero Clinical Study Site - Los Angeles
- Akero Clinical Study Site - Pasadena
Arkansas
- Akero Clinical Study Site - North Little Rock
Colorado
- Akero Clinical Study Site - Englewood
Indiana
- Akero Clinical Study Site - South Bend
Kansas
- Akero Clinical Study Site - Topeka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2021-07-30 |
| Est. Completion | 2025-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05039450
The ClinicalTrials.gov registry entry for NCT05039450 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (31% lower). The listed sponsor is Akero Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05039450 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05039450 about?
NCT05039450 is a clinical study titled "A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)". This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
What is the current status of trial NCT05039450?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2021-07-30. Estimated completion is 2025-05.
What conditions does trial NCT05039450 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT05039450?
The interventions under investigation include: Placebo (DRUG), EFX (DRUG).
Who is sponsoring clinical trial NCT05039450?
This trial is sponsored by Akero Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05039450 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
ACTIVE NOT RECRUITING · Phase 2
-
Statins for the Treatment of NASH
ACTIVE NOT RECRUITING · Phase 2
-
Tocotrienol Against the Progression of End Stage Liver Disease
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
COMPLETED · Phase 2
-
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.